BV Monotherapy (sALCL)

Background

Phase II, single-arm, pivotal study. 58 patients with relapsed/refractory systemic anaplastic large cell lymphoma (sALCL) after ≥1 prior therapy. Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate (MMAE payload); sALCL universally expresses CD30. This study led to the first BV approval in T-cell lymphoma and established its single-agent activity in sALCL.

Interventions and follow up

Regimen: Brentuximab vedotin 1.8 mg/kg IV every 3 weeks (max 16 cycles) in R/R sALCL
Primary endpoint: Overall response rate (independent review committee)
Median follow-up: ~6 years (long-term update)

Results

ORR (primary): 86% (95% CI 75–94%)
CR rate: 57%
Median DoR (all responders): not reached at 6-year follow-up
Median OS: not reached (CR patients in remission at ~6 years)
Durability: no progressions observed beyond 40 months in CR patients

Adverse events

Neurologic: Peripheral neuropathy any grade 42% (grade ≥3 12%); improved/resolved in ~80% after dose modification or discontinuation
Hematologic: Grade ≥3 neutropenia 21%; grade ≥3 thrombocytopenia 5%
Constitutional: Fatigue any grade 41%

Conclusions

Brentuximab vedotin achieved an 86% ORR (57% CR) in R/R sALCL with remarkable durability, with no progressions beyond 40 months in CR patients, suggesting potential cure in a significant subset, one of the highest and most durable single-agent outcomes ever reported in R/R T-cell lymphoma.

Key Limitations

Single-arm Phase II with small sample (n=58) and no comparator. Cumulative peripheral neuropathy is the dose-limiting toxicity. Results are specific to CD30-high sALCL and do not generalize to CD30-low PTCL subtypes.

Clinical Context

This trial led to FDA approval of BV for R/R sALCL (2011). Activity in this study underpinned the subsequent frontline ECHELON-2 trial (BV-CHP), now a standard of care for CD30-positive PTCL. ESMO guidelines recommend BV for R/R sALCL and CD30-expressing PTCL.

References